Keyword: NIAID

Amid the COVID-19 pandemic, many teams of researchers are working on potential vaccines. We asked experts to assess progress—and point out challenges.

After the president touted a hydroxychloroquine as a potential COVID-19 treatment, shortages have popped up. Some patients need the med to survive.

NIH and Moderna will need a coronavirus vaccine manufacturer, and and no major pharmaceutical company has stepped up.

Amgen buys out Astellas Japanese joint venture. Sun Piaoyang steps down as Hengrui chairman. Moderna-NIH and Inovio work on coronavirus vaccines.

IDT Biologika has a new human vaccine manufacturing facility as its narrows its focus to the development and production of human vaccines only.

If the German contract manufacturer delivers all projects over the 10-year course, it could receive up to $80 million.

Through an ongoing "challenge" study, FluGen hopes to see whether the nasal vaccine can fight off the flu virus that doesn't match its own.

Zika vaccine research continues in the absence of a large-scale outbreak, but a shortage of cases is making it hard to test for efficacy.

Here is some other vaccine news of note for the week.

Johnson & Johnson's "mosaic" HIV vaccine regimen elicited immune responses one year after the final shot.